Zacks Investment Research upgraded shares of Innate Pharma (NASDAQ:IPHYF) from a sell rating to a hold rating in a research report report published on Wednesday.
According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “
Separately, HC Wainwright assumed coverage on shares of Innate Pharma in a research report on Wednesday, August 30th. They set a buy rating on the stock.
Shares of Innate Pharma (IPHYF) opened at $10.80 on Wednesday.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Innate Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Innate Pharma and related companies.